泽璟制药：获得药物临床试验批准通知书

Core Viewpoint - Zai Lab has received approval from the National Medical Products Administration for a clinical trial of its injectable drug ZG006 in combination with PD-1/PD-L1 immune checkpoint inhibitors and chemotherapy for small cell lung cancer [1] Group 1 - The clinical trial approval is a significant milestone for Zai Lab, indicating progress in its oncology pipeline [1] - The combination therapy aims to enhance treatment efficacy for patients with small cell lung cancer, a challenging cancer type [1] - This approval may position Zai Lab favorably in the competitive oncology market, potentially leading to future revenue growth [1]